ClinicalTrials.gg
RecruitingNCT06975111Updated Nov 4, 2026

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

A Phase 2/3 interventional study of Metformin and semaglutide in Menopause, Menopause Hot Flashes and Menopause Related Conditions, sponsored by University of Colorado, Denver. Recruiting at 3 sites in United States. Open to female participants aged 45 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Colorado, Denver · Phase 2/3, Interventional, and Treatment

How we know · 12 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 3, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
45 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Planned enrollment
10th of 16
200 · median 249
Started
2026
with 2 others
Phase 2/3
Only one
of the 16
Registered
14th of 16
by date
Lead sponsor
1 of 16
University of Colorado, Denver

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 2/3, and was the 14th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Hot Flashes studies recruiting now, 13 (35%) set no upper age limit and 22 (59%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.

03

Conditions studied

  • Menopause
  • Menopause Hot Flashes
  • Menopause Related Conditions
  • Cardiovascular

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
45 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 45-55
  • In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea
  • No current use of systemic hormone therapy or hormonal , other than progestin-releasing IUDs or oral, micronized progesterone. Vaginal (non-systemic) estrogen use (FDA-approved products only, used as labelled) is permitted and is NOT an exclusion. Other forms of non-FDA approved hormones will need to be reviewed by the study physicians on-site to determine eligibility. Women choosing to discontinue hormonal contraception and/or systemic hormone therapy may become eligible for the study after a
  • Presence of a uterus and at least one ovary in order to track menstrual patterns
  • Have a smartphone and broadband access adequate to accept telehealth appointments
  • No more than 5% weight loss in the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)
  • Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.
  • Pregnancy or actively trying to get pregnant
  • Inability to adhere to study protocol schedule
  • Untreated alcoholism
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a > 30 kg/m2.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Preventative Health Advice

    Participants will be given preventative health advice and asked to wear an activity \& sleep monitor.

    Behavioral: Life style intervention · Drug: Fezolinetant · Drug: Hormonal therapy

  • Active comparator
    At Risk for Heart Disease

    Medications will be given to each participant in this arm that lowers your heart disease risk.

    Drug: Metformin · Drug: Anti-hypertensives · Drug: Lipid Lowering Medication · Behavioral: Life style intervention

  • Active comparator
    Overweight Women

    Women who fit in this category will receive medication for lowering insulin resistance and/or a weight loss medication.

    Drug: Metformin · Drug: semaglutide

  • Active comparator
    Women with Obesity

    Women that are over a BMI of 30 kg/m2 will be offered a GLP-1 antagonist.

    Drug: semaglutide

  • Active comparator
    Women With Hot Flashes

    Women with Hot flashes will have either hormonal or non-hormonal medication to reduce the number and/or severity of hot flashes.

    Drug: Fezolinetant · Drug: Hormonal therapy

Interventions

  • Metformin will be given to participants who have a elevated HbA1c and also for weightloss.

  • Overweight women and women with obesity will take Semaglutide for weight-loss

  • DrugAnti-hypertensives

    a. Antihypertensives, with the goal of maintaining blood pressure at 130/80 or lower per ACC guidelines19. Per current clinical guidelines and standard of care, hypertension will be treated first with monotherapy using either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium channel blocker, or a thiazide diuretic provided that are no contraindications.

    Also known as: The use of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium channel blocker, or a thiazide diuretic.

  • DrugLipid Lowering Medication

    . First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.

    Also known as: The use of generic statins

  • BehavioralLife style intervention

    will simply be followed and given preventive advice (maintenance of a normal BMI and physical activity, moderation in salt intake, and no more than 1 alcoholic drink per day). They will be provided with a wearable activity monitor. This advice will be based on guidelines by the American Heart Association and the Menopause Society.

  • Women with menopausal symptoms will be treated with hormone therapy (estrogen and progesterone) if appropriate, or with a neurokinin receptor antagonist (Fezolinetant). This can be treatment for women in any arm of the study as well as an arm by its self.

  • DrugHormonal therapy

    Participants will be treated with estrogen and/or progesterone for treatment of hot flashes in women during the study.

06

What researchers measure

Primary outcomes

  1. Epigenetic aging measurements of "PhenoAge"

    Change in epigenetic aging, as assessed by PhenoAge. PhenoAge calculates a biological age score based on key biomarkers circulating in the bloodstream. A lower PhenoAge score suggests slower biological aging, while a higher score indicates accelerated aging.

    Time frame: Up to 2 years

  2. Epigenetic aging measurements of "GrimAge"

    Epigenetic aging, as assessed by GrimAge. GrimAge assesses lifespan from examining DNA Methylation.

    Time frame: Up to 2 years

Secondary outcomes

  1. IL-1

    Inflammatory IL-1 serum levels, examined to determine a person's inflammatory state. Higher levels of IL-1 can indicate more inflammation. Being in an "inflamed state" can have detrimental effects on a woman's health.

    Time frame: Up to 2 years

  2. TNF-alpha

    Serum inflammatory marker TNF-alpha. Higher levels of TNF-alpha can indicate more inflammation. TNF-alpha is examined to determine a person's inflammatory state.

    Time frame: Up to 2 years

  3. IL-6

    Serum IL-6 levels. IL-6 is examined to determine a person's inflammatory state. Higher levels of IL-6 indicate more inflammation. Being in an "inflamed state" can have detrimental effects on a women's health.

    Time frame: Up to 2 years

  4. IL-8

    IL-8 serum levels. IL-8 is examined to determine a person's inflammatory state. Higher levelf of IL-8 indicate more inflammation. Being in an "inflamed state" can have detrimental effects on a women's health.

    Time frame: Up to 2 years

  5. Flow-mediated dilation

    Flow-mediated dilation measures the diameter of vascular and endothelial cell function and predicts cardiovascular event risk. The diameter of the target artery is measured by high-resolution external vascular ultrasound in response to an increase in blood flow.

    Time frame: Up to 2 years

  6. Serum Marker for Ovarian Aging

    Anti-mullerian hormones (AMH) serum levels will be analyzed. AMH is an indicator of ovarian aging and reflects egg supply. Lower levels of AMH indicate a lower egg supply.

    Time frame: Up to 2 years

  7. MENQOL survey

    Menopause-specific Quality of Life (MENQOL) measures quality of life in menopausal women. It is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor, psychosocial, physical, and sexual. There will be a overall score and we are examining if there is a change in response to treatment.

    Time frame: Up to 2 years

  8. Eaotoxin levels

    Eaotoxin is a inflammatory marker that increases when there is an inflammed state in a woman. Serum Eaotoxin will be measured before, during and at the end of the study.

    Time frame: Up to 2 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992 Jul 18;305(6846):160-4. doi: 10.1136/bmj.305.6846.160. PubMed 1285753 ↗
  • SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. PubMed 26551272 ↗
  • Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, Johnston J, Karlamangla AS. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009 May 26;72(21):1850-7. doi: 10.1212/WNL.0b013e3181a71193. PubMed 19470968 ↗
  • Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009 Dec 15;54(25):2366-73. doi: 10.1016/j.jacc.2009.10.009. PubMed 20082925 ↗
  • Samargandy S, Matthews KA, Brooks MM, Barinas-Mitchell E, Magnani JW, Janssen I, Kazlauskaite R, El Khoudary SR. Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study. Menopause. 2021 Mar 1;28(6):626-633. doi: 10.1097/GME.0000000000001755. PubMed 33651741 ↗
  • Tanaka T, Basisty N, Fantoni G, Candia J, Moore AZ, Biancotto A, Schilling B, Bandinelli S, Ferrucci L. Plasma proteomic biomarker signature of age predicts health and life span. Elife. 2020 Nov 19;9:e61073. doi: 10.7554/eLife.61073. PubMed 33210602 ↗
  • Thurston RC, Carroll JE, Levine M, Chang Y, Crandall C, Manson JE, Pal L, Hou L, Shadyab AH, Horvath S. Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI). J Clin Endocrinol Metab. 2020 Apr 1;105(4):1221-7. doi: 10.1210/clinem/dgaa081. PubMed 32080740 ↗
  • Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, Leipold MD, Lin DTS, Kobor MS, Horvath S. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019 Dec;18(6):e13028. doi: 10.1111/acel.13028. Epub 2019 Sep 8. PubMed 31496122 ↗
  • Thurston RC, Aslanidou Vlachos HE, Derby CA, Jackson EA, Brooks MM, Matthews KA, Harlow S, Joffe H, El Khoudary SR. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. J Am Heart Assoc. 2021 Feb 2;10(3):e017416. doi: 10.1161/JAHA.120.017416. Epub 2021 Jan 20. PubMed 33470142 ↗
  • Hedderson MM, Liu EF, Lee C, El Khoudary SR, Gold EB, Derby CA, Thurston RC. Vasomotor Symptom Trajectories and Risk of Incident Diabetes. JAMA Netw Open. 2024 Oct 1;7(10):e2443546. doi: 10.1001/jamanetworkopen.2024.43546. PubMed 39480425 ↗
  • Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, Michos ED, Minissian M, Pepine C, Vaccarino V, Volgman AS; ACC CVD Womens Committee Members. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 May 26;75(20):2602-2618. doi: 10.1016/j.jacc.2020.03.060. PubMed 32439010 ↗
  • Patel D, Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Hamid P. The Effectiveness of Metformin in Diabetes Prevention: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep 28;15(9):e46108. doi: 10.7759/cureus.46108. eCollection 2023 Sep. PubMed 37900422 ↗
  • Santoro N, Kuhn K, Pretzel S, Schauer IE, Fought A, D'Alessandro A, Stephenson D, Bradford AP. A high-fat eucaloric diet induces reprometabolic syndrome of obesity in normal weight women. PNAS Nexus. 2023 Dec 18;3(1):pgad440. doi: 10.1093/pnasnexus/pgad440. eCollection 2024 Jan. PubMed 38178979 ↗
  • Legro RS, Hansen KR, Diamond MP, Steiner AZ, Coutifaris C, Cedars MI, Hoeger KM, Usadi R, Johnstone EB, Haisenleder DJ, Wild RA, Barnhart KT, Mersereau J, Trussell JC, Krawetz SA, Kris-Etherton PM, Sarwer DB, Santoro N, Eisenberg E, Huang H, Zhang H; Reproductive Medicine Network. Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial. PLoS Med. 2022 Jan 18;19(1):e1003883. doi: 10.1371/journal.pmed.1003883. eCollection 2022 Jan. PubMed 35041662 ↗
  • Tannous A, Bradford AP, Kuhn K, Fought A, Schauer I, Santoro N. A randomised trial examining inflammatory signaling in acutely induced hyperinsulinemia and hyperlipidemia in normal weight women-the reprometabolic syndrome. PLoS One. 2021 Mar 25;16(3):e0247638. doi: 10.1371/journal.pone.0247638. eCollection 2021. PubMed 33764994 ↗
  • Mogul HR, Freeman R, Nguyen K, Frey M, Klein LA, Jozak S, Tanenbaum K. Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain. PLoS One. 2014 Sep 26;9(9):e108264. doi: 10.1371/journal.pone.0108264. eCollection 2014. PubMed 25259787 ↗
  • Mogul H, Freeman R, Nguyen K. METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. Endocr Pract. 2016 May;22(5):575-86. doi: 10.4158/EP151087.OR. Epub 2016 Jan 20. PubMed 26789348 ↗
  • "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. PubMed 35797481 ↗
  • Simpson DJ, Chandra T. Epigenetic age prediction. Aging Cell. 2021 Sep;20(9):e13452. doi: 10.1111/acel.13452. Epub 2021 Aug 20. PubMed 34415665 ↗
  • Karlamangla AS, Shieh A, Greendale GA. Hormones and bone loss across the menopause transition. Vitam Horm. 2021;115:401-417. doi: 10.1016/bs.vh.2020.12.016. Epub 2021 Jan 29. PubMed 33706956 ↗
  • Moreau KL, Hildreth KL, Klawitter J, Blatchford P, Kohrt WM. Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress. Geroscience. 2020 Dec;42(6):1699-1714. doi: 10.1007/s11357-020-00236-7. Epub 2020 Aug 8. PubMed 32770384 ↗
  • Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med. 2008 Jul 28;168(14):1568-75. doi: 10.1001/archinte.168.14.1568. PubMed 18663170 ↗
  • El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition. Menopause. 2013 Jan;20(1):8-14. doi: 10.1097/gme.0b013e3182611787. PubMed 22990755 ↗
  • Bromberger JT, Epperson CN. Depression During and After the Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants of Disease. Obstet Gynecol Clin North Am. 2018 Dec;45(4):663-678. doi: 10.1016/j.ogc.2018.07.007. Epub 2018 Oct 25. PubMed 30401549 ↗
  • El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, Karvonen-Gutierrez C, Waetjen LE, Matthews K. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019 Oct;26(10):1213-1227. doi: 10.1097/GME.0000000000001424. PubMed 31568098 ↗

Individual participant data

Plan to share: Undecided — We will share the information but have not developed the exact plan to share. All information and data will be de-identified prior to sharing. To share the data we will require a proposal detailing the use if IPD.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Oct 2029, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 16, 2025
StartActual
Mar 1, 2026
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 1, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 2 added, 1 removed; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • EditedIn the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18amenorrhea
  • RemovedNo current use of hormone therapy or hormonal contraception
  • AddedNo current use of systemic hormone therapy or hormonal contraception, other than progestin-releasing IUDs or oral, micronized progesterone. Vaginal (non-systemic) estrogen use (FDA-approved products only, used as labelled) is permitted and is NOT an exclusion. Other forms of non-FDA approved hormones will need to be reviewed by the study physicians on-site to determine eligibility. Women choosing to discontinue hormonal contraception and/or systemic hormone therapy may become eligible for the study after a washout period
  • AddedNo more than 5% weight loss in the last 3 months
Exclusion criteria
  • RemovedUn- Diagnosed abnormal uterine bleeding
Nov 3, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University of Colorado-School of Medicine · Aurora, United StatesContact added c•••@cuanschutz.edu · •••5276Contact added (no phone or email listed)
  • Virginia Commonwealth University · Richmond, United StatesContact K•••@vcuhealth.org · •••5159→B•••@vcuhealth.org · •••4849Contact K•••@vcuhealth.org→B•••@vcuhealth.org
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of Colorado-School of Medicine · Aurora, United StatesContact added c•••@cuanschutz.edu · •••5276Contact added (no phone or email listed)
    • Virginia Commonwealth University · Richmond, United StatesContact K•••@vcuhealth.org · •••5159→B•••@vcuhealth.org · •••4849Contact K•••@vcuhealth.org→B•••@vcuhealth.org
  2. Nov 3, 2026
    Eligibility 1 inclusion criterion edited, 2 added, 1 removed; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • EditedIn the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18amenorrhea
    • RemovedNo current use of hormone therapy or hormonal contraception
    • AddedNo current use of systemic hormone therapy or hormonal contraception, other than progestin-releasing IUDs or oral, micronized progesterone. Vaginal (non-systemic) estrogen use (FDA-approved products only, used as labelled) is permitted and is NOT an exclusion. Other forms of non-FDA approved hormones will need to be reviewed by the study physicians on-site to determine eligibility. Women choosing to discontinue hormonal contraception and/or systemic hormone therapy may become eligible for the study after a washout period
    • AddedNo more than 5% weight loss in the last 3 months
    Exclusion criteria
    • RemovedUn- Diagnosed abnormal uterine bleeding
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06975111
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Mar 1, 2026
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Carrie Hsu, BA
Contact
carrie.hsu@cuanschutz.edu
303-724-5276
Nalia Naushad
Contact
naila.naushad@cuanschutz.edu
Nanette Santoro, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Fezolinetant

Start the discussion